Marksans Pharma has announced the establishment of two fully owned subsidiaries in Ireland and Canada, marking a significant step in the company's international expansion strategy. The pharmaceutical company's move to create these subsidiaries demonstrates its commitment to strengthening its global operational footprint.

Strategic International Expansion

The establishment of subsidiaries in both Ireland and Canada represents a strategic initiative to enhance the company's pharmaceutical operations in key international markets. These new entities will operate as fully owned subsidiaries, providing Marksans Pharma with direct control over its operations in these regions.

Market Positioning

The decision to establish operations in Ireland and Canada positions Marksans Pharma to better serve these important pharmaceutical markets. Ireland serves as a strategic gateway to European markets, while Canada represents a significant North American opportunity for the company's pharmaceutical products and services.

Operational Framework

Both subsidiaries will focus on pharmaceutical operations, aligning with Marksans Pharma's core business activities. The fully owned structure of these subsidiaries will enable the company to maintain operational control and implement its business strategies effectively in these new markets.

Marksans Pharma Ltd has announced its quarterly earnings conference call to discuss the unaudited financial results for the third quarter of fiscal year 2026. The company informed stock exchanges about this scheduled investor interaction through a regulatory filing under Regulation 30 of SEBI listing requirements.

Conference Call Schedule

The earnings conference call has been scheduled for the following details:

Management Participation

The company's senior leadership will represent Marksans Pharma during the investor call:

• Mark Saldanha - Founder, Chairman and Managing Director
• Jitendra Sharma - Chief Financial Officer
• Nitin Agarwal - Analyst, DAM Capital Advisors Ltd (Call Leader)

Access Information

Investors and analysts can participate in the conference call through multiple dial-in options. The company has provided universal access numbers (+91 22 6280 1384, +91 22 7115 8285) accessible from all networks and countries. International participants can use dedicated toll-free numbers for Hong Kong, Singapore, UK, and USA.

Documentation and Records

Following the conference call, Marksans Pharma will make comprehensive documentation available to stakeholders. The company has confirmed that the presentation materials, complete audio recording of the call, and detailed transcript will be hosted on the company's official website at marksanspharma.com under the earnings call transcripts section.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Harshavardhan Panigrahi signed the regulatory communication sent to both BSE Limited and National Stock Exchange of India Limited on January 22, 2026.